The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
|Articles|June 2, 2016
- Pharmaceutical Technology-06-02-2016
- Volume 40
- Issue 6
Dropper Eliminates Need for Isolation and Insertion
The MD-Dropper Cap from HealthStar is a new dropper bottle technology for blow-fill-seal (BFS) technology.
The MD-Dropper Cap from HealthStar is a new dropper bottle technology for blow-fill-seal (BFS) technology. The design produces metered-dose eye drops with standard BFS technology, without the added step of isolation/insertion technology. The containers are molded using standard BFS manufacturing machines and procedures. Cycle times are maintained at normal BFS output levels, typically around 12 seconds. The pre-assembled and sterilized containers are snapped onto the BFS containers post manufacturing in a cleanroom environment. The contents of the bottle are never in contact with the MD-Dropper Cap until activated by the patient.
Articles in this issue
over 10 years ago
Modern Manufacturing Comes of Ageover 10 years ago
Examining Blow-Fill-Seal Technology for Aseptic Processesover 10 years ago
Demonstrating a State of Controlover 10 years ago
PAT: “Gateway Drug” to the 21st Century for the Pharma Industryover 10 years ago
Watch Out for the Hangoverover 10 years ago
Deciding When To Use Modular Constructionover 10 years ago
Integrating Single-Use Systems in Pharma Manufacturingover 10 years ago
Steps Closer to the Adoption of Continuous Processingover 10 years ago
Industry Moves Closer to Continuous ManufacturingRelated to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Trending on Pharmaceutical Technology
1
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up
4
PharmTech Weekly Roundup—September 18, 2026
5